Ebola Vaccines and Treatments Dispatched to the Democratic Republic of the Congo

Vaccination of frontline health workers and contacts of people infected with Ebola virus disease has begun in Bulape health zone in the Democratic Republic of the Congo (DRC) 's Kasai Province, where an outbreak of the disease was declared.

The World Health Organization (WHO) stated on September 14, 2025, that an initial 400 doses of the Ervebo® Ebola vaccine, prepositioned in the capital, Kinshasa, have been delivered to Bulape, one of the current hotspots of the DRC's 16th Zaire Ebolavirus outbreak.

Additional Ervebo doses will be delivered to the affected localities in the coming days.

In addition, treatment courses of the Ebanga™ monoclonal antibody therapy (Mab114) drug have also been sent to treatment centres in Bulape for clinical care.

In the outbreak area, WHO has so far deployed 48 experts in disease surveillance, clinical care, infection prevention and control, logistics, and community engagement.

In countries neighboring the DRC, the WHO is working with national authorities to bolster operational readiness, enabling the rapid detection of Ebola cases and the prompt initiation of measures to curb further spread of the lethal virus.

As of September 15, 2025, the WHO assesses the overall public health risk posed by the ongoing outbreak as high at the national level, moderate at the regional level, and low at the global level.

To alert international travelers, the U.S. CDC issued a Level 1 - Practice Usual Precautions, Travel Health Advisory regarding this Ebola outbreak. 

The CDC wrote on September 8, 2025: "While not commercially available, there is an FDA-approved vaccine for the prevention of the Zaire Ebola virus." It is presently available to select individuals in specific occupations (e.g., outbreak responders).

For more information on vaccines, please consult with your healthcare provider to discuss eligibility and access to the Ebola vaccine.